-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology ELISpot platform: a precise, efficient and multi-functional immune research tool
Author:
InnoModels
Release time:
2024-07-26
In the vast universe of life science research, immunology research has always occupied a pivotal position. InnoModels Biotechnology (Beijing) Co., Ltd. relies on its cutting-edge ELISpot platform to provide researchers in this field with strong technical support and solutions. This article will deeply explore the characteristics of InnoModels' ELISpot platform and demonstrate its unique charm in immunology research.
High sensitivity: the dazzling eye to capture subtle changes
InnoModels' ELISpot platform is known for its excellent high sensitivity. This technology can accurately detect proteins secreted by individual cells, including trace molecules such as cytokines and antibodies. This high degree of sensitivity allows researchers to capture subtle changes in immune cell responses, allowing for a more comprehensive assessment of the quantity and quality of immune responses. This feature is particularly important in areas such as cancer vaccine research, autoimmune diseases, and the study of infectious pathogens, because it can help scientists more accurately assess treatment effects and disease progression.
Versatility: a toolbox for diverse research needs
InnoModels' ELISpot platform is not only highly sensitive but also highly versatile. The platform supports multiple CTL (cytotoxic T lymphocyte) stimulation modalities, including in vitro specific antigen presentation using human or mouse peripheral blood mononuclear cells (PBMCs) or spleen immune cells. In addition, the platform can also analyze CTL responses in peripheral blood or spleen cells following immunization in immunocompetent mice. This flexibility allows researchers to choose appropriate stimulation methods and detection methods according to different experimental needs, thereby more accurately assessing the function and activity of CTLs.

Precise quantification: the quantitative ruler for scientific research
The ELISpot platform provides the ability to perform quantitative and qualitative analysis of CTL production levels. This feature allows researchers to comprehensively assess the quantity and quality of CTL responses to more accurately judge the effectiveness of immunotherapy. In tumor vaccine research and cancer immunotherapy, understanding and monitoring CTL responses is crucial. InnoModels' ELISpot platform provides strong support for these studies by providing precise quantitative scales.
Close to clinical practice: assisting drug development and personalized medicine
InnoModels not only excels in basic research, but its ELISpot platform is also widely used in drug research and development and personalized medicine. Through the PDC in vitro high-throughput drug efficacy evaluation platform, InnoModels Biotechnology uses the digestion products of the PDX (human tumor xenograft) model to obtain primary cells that are highly consistent with patients, providing highly precise drug efficacy for drug development and clinical treatment. evaluate. The application of this platform is not limited to drug screening, but can also predict the clinical effectiveness of drugs, providing a reliable basis for the development and clinical application of new drugs.
Excellent service: Comprehensive support for scientific researchers on their path of exploration
As a company that focuses on customer satisfaction, InnoModels Biotechnology not only provides advanced ELISpot technology, but is also committed to providing users with comprehensive training and technical support. Through online training, seminars and professional technical support teams, InnoModels Biotechnology ensures that users can fully understand and correctly apply ELISpot technology to maximize its advantages. This comprehensive service makes researchers more comfortable on the road of exploration.
Conclusion
In summary, InnoModels Biotechnology ELISpot platform plays an irreplaceable role in the fields of immunology research, biomedical research, and drug development due to its high sensitivity, versatility, precise quantification, and clinical closeness. With the continuous advancement of science and technology and the in-depth development of research, it is believed that InnoModels Biotechnology ELISpot platform will show broader development prospects and application value in the future.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd